SCHEMBL1780938

SCHEMBL1780938

Clc1ccccc1N1CCN(CCCCOc2ccc(Cn3nccn3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.57
DRD3 P35462 8/20 0.57
DRD4 P21917 3/20 0.57
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
HTR1A P08908 2/20 0.52
HTR7 P34969 1/20 0.52
LMNA P02545 3/20 0.51
KDM4E B2RXH2 1/20 0.51
KCNH2 Q12809 1/20 0.51
HTR2A P28223 1/20 0.51
MAOA P21397 2/20 0.51
MAOB P27338 2/20 0.51
ALDH1A1 P00352 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 1/20 0.50
NLRP1 Q9C000 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1114606 0.87 DRD2 (0.55) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL1114854 0.87 LMNA (0.69) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL12403727 0.84 HRH3 (0.62) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL1114549 0.83 DRD2 (0.52) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL1114455 0.83 DRD2 (0.51) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL1114667 0.81 HRH3 (0.59) DRD2DRD3SLC6A2SLC6A4HTR1A
SCHEMBL1114397 0.81 DRD2 (0.60) DRD2DRD3DRD4HTR1AKCNH2
SCHEMBL3614911 0.79 DRD3 (0.86) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL1114668 0.78 LMNA (0.67) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL4235263 0.77 DRD2 (0.51) DRD2DRD3DRD4SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP claimed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US claimed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US claimed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US claimed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US claimed
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP disclosed
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US disclosed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US disclosed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US disclosed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US disclosed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US disclosed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
WO-2009145591-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF HTR5A, HTR1A, HTR2A DRD2 62/4885DRD3 148/4885DRD4 115/4885
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF HTR5A, HTR1A, HTR2A DRD2 60/4885DRD3 147/4885DRD4 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.